FDA Establishes Final Guidelines for Psychedelic Drug Clinical Trials

The U.S. Food and Drug Administration has finalized its comprehensive guidance for conducting clinical trials involving psychedelic drugs. This document provides a critical framework for researchers, addressing aspects from manufacturing and safety to trial design and the unique challenge of maintaining blinding in such studies. The move signals a more structured pathway for the development and evaluation of these substances for potential medical uses.